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Abstract: Triosephosphate isomerase (TIM), a central enzyme in the glycolytic pathway, has
been the subject of extensive structural and mechanistic investigations over the past 30 years.
The TIM barrel is the prototype of the (β/α)8 barrel fold, which is one of the most extensively
used structural motifs in enzymes. Mechanistic studies on TIM from a variety of sources have
emphasized the importance of loop 6 dynamics for enzyme activity. Several conserved
residues in TIM have been investigated by extensive site-directed mutagenesis of the enzyme
from yeast, chicken, and trypanosoma. The cloning and sequencing of the TIM gene from the
malarial parasite Plasmodium falciparum in 1993 revealed the unexpected mutation of a
hitherto conserved residue serine (S96) to phenylalanine (F96). Subsequent results from the
genome sequencing programs of Plasmodium falciparum, Plasmodium vivax, and
Plasmodium yoelii confirmed the presence of the S96F mutation in malarial parasites. The
crystal structure of PfTIM and several inhibitor complexes, including a high-resolution
(1.1 Å) structure of the PfTIM 2-phosphoglycerate complex, revealed that loop 6 had a
propensity to remain open, even in several ligand bound structures. Furthermore, both open
and closed forms could be characterized for the same complex. Since glycolysis is the pri-
mary source of ATP for the malarial parasite during the intraerythrocytic stage, glycolytic en-
zymes present themselves as potential targets for inhibitors. Two distinct approaches have
been explored. The use of dimer interface peptides, which interfere with assembly, has
proved promising. Inactivation of the enzyme by modification of a cysteine (C13) residue,
which lies close to the active site residue, lysine (K12) is another potential strategy. The dif-
ferential reactivity, of the four-cysteine residues, at positions 13, 126, 196, and 217 in each
subunit has been established using electrospray ionization mass spectrometry. Studies of sin-
gle tryptophan mutants (W11F and W168F) of PfTIM provide a probe to study folding, sta-
bility, and inhibitor interactions. 
INTRODUCTION
Triosephosphate isomerase (TIM) is a well-studied, glycolytic enzyme that catalyzes the interconver-
sion of dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. Banner et al. [1] reported the first
crystal structure of TIM from chicken breast muscle in 1975. The structure has eight α-helices alter-
nating with eight β-strands along the polypeptide chain. The parallel β-strands are hydrogen-bonded to
each other and form a central, solvent-excluded, eight-stranded β-barrel. The eight helices wrap around
the central β-barrel. The strands and helices are arranged approximately antiparallel to each other. This
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fold is popularly known as the “TIM barrel” fold, as it was the first structure to be determined in this
family. A large body of structure–function correlations based on site-directed mutagenesis of the en-
zymes from yeast, chicken, rabbit, and trypanosoma have provided many insights into catalytic mech-
anisms [2–5]. Knowles states that “this enzyme (TIM) appears to have arrived at the end of its evolu-
tionary development as a catalyst” [6]. Specific roles have been ascribed to many of the conserved
residues like glutamate, histidine, and lysine. Cloning and sequencing of the TIM gene from the malar-
ial parasite Plasmodium falciparum revealed interesting differences from those of other reported TIMs,
notably serine 96(S96); a completely conserved residue in all TIM sequences hitherto reported was re-
placed by a phenylalanine (F) residue [7]. The availability of the recombinant parasite enzyme
prompted us to undertake detailed analysis of the effects of site-directed mutations on folding, stability,
and activity [8–11].
The search for new antimalarial drugs continues with unabated vigor because of the increased
spread of the disease, with P. falciparum infection causing the most lethal form of malaria. The grow-
ing problem of drug resistance in malaria highlights the need to quickly develop effective, new anti-
parasitic agents. In the intraerythrocytic phase of the parasite life cycle, glycolysis is estimated to be the
predominant pathway for ATP production, making glycolytic enzymes an attractive target for inhibitory
intervention [12–13]. Malarial parasites appear to lack a functional TCA cycle. Three-dimensional
structures are available for all the enzymes of the glycolytic pathway, with at least one member of each
class structurally characterized from different sources. However, there is limited amount of structural
information on glycolytic enzymes from P. falciparum, as shown schematically in Fig. 1.
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Fig. 1 Glycolytic pathway, with available crystal structures of proteins from Plasmodium species. Only monomeric
structures of the enzymes are shown; TIM [14], aldolase [15], and phosphoglycerate kinase [16] are illustrated
using PDB coordinate sets 1YDV, 1A5C, and 1LTK, respectively.
Triosephosphate isomerase from P. falciparum (PfTIM) was cloned and expressed by Ranie et al.
in E. coli [7]. Table 1 compares the kinetic properties of PfTIM with the enzymes from other sources.
Figure 2 shows the sequence alignment of TIM from various organisms. In addition to the S96F muta-
tion, another important difference between the human and Plasmodium TIMs is the M13C mutation,
which occurs at the dimer interface. The S96F mutation is also observed in other Plasmodium species
such as Plasmodium vivax and Plasmodium yoelii. The M13C mutation is also seen in other parasitic
TIMs (e.g., Trypanasoma, Leishmania). In principle, differences between human and parasite enzymes
are of interest in the design of selective inhibitors. PfTIM has been shown to be an extremely robust
(β/α)8 barrel which retains considerable structure even in 8 M urea [8]. Biophysical studies on folding
and stability of the wild-type enzyme and on interface mutants have permitted an analysis of the un-
folding process. The interface mutants have also permitted the dissection of the processes of subunit
dissociation and polypeptide unfolding [9–10]. 
Table 1 Kinetic properties of TIM from different sources for
the conversion of glyceraldehyde-3-phosphate to
dihydroxyacetone phosphate [10].
Source Km (mM) kcat × 105 (min–1)
P. falciparum 0.35 ± 0.16 2.68 ± 0.84
Chicken 0.47 2.56
Yeast 0.62 ± 0.05 1.41 ± 0.36
T. brucei 0.25 ± 0.05 3.7
© 2005 IUPAC, Pure and Applied Chemistry 77, 281–289
Plasmodium falciparum triosephosphate isomerase 283
Fig. 2 Sequence alignment of triosephosphate isomerase from different sources. The alignment was performed
using the Clustal W (multiple alignment) program.
STRUCTURES OF PfTIM INHIBITOR COMPLEXES AND LOOP 6 DYNAMICS
The crystal structure of PfTIM was first reported at 2.2 Å, in 1997 [14]. Figure 3a shows a view of the
fold of the monomer illustrating the active site residues (H95, K12, E165). Figure 3b is a view of the
dimer interface and also shows the location of Trp11, Trp168, and Cys-13. Strategies for enzyme inhi-
bition generally target active sites or the subunit interfaces in the case of multimeric enzymes [17–18].
The structures of several PfTIM inhibitor complexes have been determined (Table 2) [19–21].
The high-resolution structure of the PfTIM-2-phosphoglycerate complex has been reported at 1.1 Å
[21]. A noticeable feature of the PfTIM inhibitor complexes is the tendency of loop 6 (residues from
166–176) to remain in the open conformation, even when the active site is occupied by a ligand. This
is in contrast to the structures of TIMs from other sources, where loop open forms are observed for un-
ligated enzymes and loop closed forms are observed upon ligand binding. The sole exception is the
structure of the trypanosomal TIM complex with N-hydroxy-4-phosphonobutanamide, where a loop
open form was previously characterized [22]. Figure 4 shows a comparison of the loop open and closed
states of PfTIM, illustrating a movement of approximately 6–7 Å of the tip of the loop upon closure. A
possible reason advanced for the tendency of loop 6 to remain open in the ligand bound state in PfTIM
was the potential steric clash between F96 and I170 in the closed form [19]. The crystal structure of the
PfTIM-phosphoglycolate complex yielded two crystal forms orthorhombic (P212121) and monoclinic
(C2). Curiously, in the orthorhombic form loop 6 was in an open conformation, while in the monoclinic
form the closed conformation was observed. In the latter form, steric clashes were avoided by F96
adopting an alternate side-chain orientation. In the 1.1 Å structure of the PfTIM 2-phosphoglycerate
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Fig. 3 Structure of PfTIM. (a) monomer (subunit A) with active site residues shown. (b) PfTIM dimer with residues
W11, W168, and C13 marked. The dark region in the figure shows the dimer interface.
complex, the protein dimer forms the asymmetric unit, with one subunit showing ligand occupancy with
the loop closed, while the other has loop 6 in an open conformation.
Table 2 Crystal structures of PfTIM–ligand complexes. 
PDB code (ref.) Resolution (Å) Ligand Space group Loop status
1YDV (14) 2.2 – C121 Open
1LYX (19) 1.9 Phosphoglycolate C2 Closed
1LZO (19) 2.8 P212121 Open
1M7P (20) 2.4 Glycerol-3-phosphate P21 Open
1O5X (21) 1.1 2-Phosphoglycerate P21 Open
1M7O (20) 2.4 3-Phosphoglycerate P21 Open
Loop closure upon substrate binding has been suggested to be important in preventing the for-
mation of the cytotoxic byproduct, methyl glyoxal. Loop 6 moves as a rigid body about hinge residues
(N-terminal hinge 166–167 and C-terminal hinge 174–176). Solid-state NMR studies have shown that
the loop movement is an inherent property of the enzyme and the nature of the bound ligand affects only
the relative populations of the open and closed conformations [23]. Recent solution NMR studies have
also provided evidence for the view that loop motion and product release are concerted and might be
one of the rate-limiting steps during catalysis [24]. NMR studies have also given an estimate of the rate
of loop movement in TIM, on the order of 104 s–1 [25].
The presence of a tryptophan residue (W168) on loop 6 suggests the possibility of using fluo-
rescence spectroscopy to study loop motion and inhibitor binding. PfTIM has only two tryptophan
residues—W11 and W168. We have, therefore, constructed the single Trp mutants W11F and W168F,
permitting the deconvolution of the fluorescence spectrum of the wild-type enzyme into contributions
from individual Trp residues. Figures 5a and 5b demonstrate the significant differences in the emis-
sion maximum and quantum yields for the two Trp residues [26]. Notably, W11F exhibits an extremely
blue-shifted fluorescence (321 nm, when excited at 270 nm); a feature that may be ascribed to a
strongly immobilized indole chromophore in a polar environment [27]. Inhibitor binding results in the
selective quenching of W168, as demonstrated by the effect of addition of inhibitor (2-phosphoglyco-
late) on the fluorescence intensity of the two mutant proteins, Fig. 5c [26]. W168 is located on the face
of the loop that projects away from the bound ligand. An even more sensitive probe of ligand binding
may be generated in an engineered mutant, which has a tryptophan residue on the loop face that is
proximal to the bound ligand. Toward this end, we are currently examining a triple mutant of the type
W11F/W168F/Y164W. 
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Fig. 4 Superposition of structures of PfTIM in loop open and closed states with the inhibitor phosphoglycolate [19].
The high degree of conservation observed for loop 6 residues in available TIM sequences is in ac-
cord with the important role ascribed for loop closure in enzyme activity. A schematic view of rela-
tionship between loop closure and enzyme activity is summarized in Fig. 6.
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Fig. 5 Steady-state fluorescence emission spectra of PfTIM wild-type (wt) and single tryptophan mutants (W11F
and W168F) at pH 8.0. Spectra were recorded after excitation at (a) 270 nm (emission max were 331, 332, and
321 nm for wt, W168F and W11F, respectively); (b) 295 nm (emission max were 331, 332, and 327 nm for wt,
W168F and W11F, respectively); (c) Effect of inhibitor binding on fluorescence emission. PfTIM wild-type (=),
mutants W11F (<) and W168F (5) were incubated in the presence of increasing concentrations of inhibitor (2PGA).
Fluorescence intensities were recorded at the maxima after excitation at 295 nm and plotted as percentage of the
intensities in the absence of inhibitor [26].
Fig. 6 Schematic representation of loop conformation during catalysis. 
STRATEGIES FOR ENZYME INHIBITION
We have explored two distinct approaches to inhibit PfTIM:
• design of synthetic interface peptides, which can potentially impede subunit association and
• modification of cysteine (C13), which is proximal to the active site residue lysine (K12).
These strategies have been based on the differences between the human and parasite enzymes at
the dimer interface and the absence of C13 in the human enzyme.
Synthetic peptides corresponding to two distinct segments of the subunit interface of the triose-
phosphate isomerase (residues 9–18, ANWKCNGTLE, peptide I; residues 68–79, KFGNGSYTGEVS,
peptide II) were synthesized. A substantial fall in enzyme activity was observed in the presence of pep-
tide II, whereas peptide I did not show any appreciable inhibition (at 1000-fold molar excess of the pep-
tide). The peptide II also showed a more pronounced inhibitory effect on two interface mutants of
PfTIM (Y74C and Y74G). The IC50 value determined for peptide II was in the range of 0.6–0.8 µM,
suggesting that use of interface peptides for inhibition is a viable approach and may also provide lead
structures for potential inhibitor design [28].
PfTIM contains four cysteine residues at positions 13, 126, 196, and 217 on each subunit. Of
these, Cys-13 is present at the dimer interface and is replaced by methionine in the corresponding
human enzyme. Electrospray ionization mass spectrometry coupled with protease-mediated peptide
mapping, was used to investigate the effect of sulfhydryl labeling on the parasite enzyme, with a view
toward developing selective covalent inhibitors by targeting the interface cysteine residue. Differential
labeling of the cysteine residues by iodoacetic acid and iodoacetamide were determined. Iodoacetic acid
labeling gave a soluble, largely inactive enzyme, whereas iodoacetamide labeling led to precipitation of
the protein. It was also observed that carboxymethylation of Cys-13 results in the formation of
monomeric species. An engineered C13D mutant resembling the iodoacetic acid-modified TIM at the
interface was also analyzed. The C13D mutant exhibited reduced stability to denaturants and 7-fold re-
duction in enzymatic activity [29]. Utilization of this reactive Cys at the interface to inhibit TIM from
other parasitic organisms is well documented in the literature [30–31].
As mentioned earlier, some of the residues conserved in other TIMs are different in PfTIM and
hence may be exploited for targeting. A charged residue, glutamate (E183) at position 183 in human
TIM is replaced with a hydrophobic residue leucine in PfTIM, and this region is solvent exposed.
Hence, in PfTIM a hydrophobic patch is exposed at a position juxtaposed to a positively charged re-
gion. This site was proposed to be specifically suited for inhibitory ligands like hydrophobic anionic
molecules. This residue lies close to the active site of PfTIM. Recently, Joubart et al. [32], using the
knowledge of the crystal structure and the DOCK algorithm, have identified some lead molecules which
inhibit the enzyme, with IC50 values <100 µM. Similarly, other important sites like F96 and S73 may
be specifically utilized in inhibiting PfTIM.
CONCLUSIONS
The availability of the crystal structure of P. falciparum triosephosphate isomerase and several protein
inhibitor complexes has raised new questions about the role of loop dynamics in enzyme activity.
Critical difference between the parasite and the human enzyme suggests possible approaches to the de-
sign of new inhibitors, which target either the dimer interface or unique sulfhydryl residues.
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